AGL 7.91 Decreased By ▼ -0.09 (-1.13%)
ANL 11.30 Decreased By ▼ -0.02 (-0.18%)
AVN 84.74 Increased By ▲ 1.29 (1.55%)
BOP 6.24 Increased By ▲ 0.39 (6.67%)
CNERGY 5.69 Decreased By ▼ -0.16 (-2.74%)
EFERT 79.70 Decreased By ▼ -0.40 (-0.5%)
EPCL 65.58 Decreased By ▼ -1.71 (-2.54%)
FCCL 15.00 Decreased By ▼ -0.20 (-1.32%)
FFL 7.11 Increased By ▲ 0.07 (0.99%)
FLYNG 7.70 Decreased By ▼ -0.07 (-0.9%)
GGGL 11.70 Decreased By ▼ -0.20 (-1.68%)
GGL 17.39 Decreased By ▼ -0.26 (-1.47%)
GTECH 9.35 Increased By ▲ 0.17 (1.85%)
HUMNL 7.25 Increased By ▲ 0.05 (0.69%)
KEL 3.47 Decreased By ▼ -0.03 (-0.86%)
LOTCHEM 30.30 Decreased By ▼ -0.65 (-2.1%)
MLCF 28.40 Decreased By ▼ -0.12 (-0.42%)
OGDC 84.60 Decreased By ▼ -0.60 (-0.7%)
PAEL 16.99 Decreased By ▼ -0.12 (-0.7%)
PIBTL 6.13 Decreased By ▼ -0.02 (-0.33%)
PRL 19.49 Decreased By ▼ -0.35 (-1.76%)
SILK 1.29 No Change ▼ 0.00 (0%)
TELE 12.07 Increased By ▲ 0.02 (0.17%)
TPL 9.15 Decreased By ▼ -0.01 (-0.11%)
TPLP 20.20 Increased By ▲ 0.01 (0.05%)
TREET 26.99 Decreased By ▼ -0.11 (-0.41%)
TRG 96.86 Decreased By ▼ -0.44 (-0.45%)
UNITY 23.02 Increased By ▲ 0.19 (0.83%)
WAVES 13.30 Increased By ▲ 0.01 (0.08%)
WTL 1.46 Increased By ▲ 0.01 (0.69%)
BR100 4,338 Decreased By -23.6 (-0.54%)
BR30 15,953 Decreased By -55.9 (-0.35%)
KSE100 43,274 Decreased By -207.5 (-0.48%)
KSE30 16,389 Decreased By -86.8 (-0.53%)
World

Pfizer submits initial data for COVID-19 vaccine booster authorization

  • Pfizer has said its vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose.
Published August 16, 2021 Updated August 17, 2021

Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.

They said the third dose showed significantly higher neutralizing antibodies against the initial SARS-CoV-2 virus compared to the two doses as well as against the Beta and the highly infectious Delta variants.

Pfizer has said its vaccine's efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose. Some countries including Israel have already gone ahead with plans to give booster doses.

However, the decision by a few rich countries to buy booster shots has drawn the ire of health activists and the World Health Organization, which has called for a moratorium on boosters until at least the end of September.

Pfizer and BioNTech had said that all patients in the trial received the third shot, BNT162b2, eight to nine months after their second dose.

The drugmakers will submit the trial data to the European Medicines Agency and other regulatory authorities in the coming weeks. They said results from a late-stage trial of the third dose are expected shortly.

Last week, U.S regulators authorized a third dose of COVID-19 vaccines by Pfizer-BioNTech and Moderna Inc for people with compromised immune systems who are likely to have weaker protection from the two-dose regimens.

Comments

Comments are closed.